Cincinnati-based contract research organisation Medpace has announced its second acquisition this year, scooping up the medical device expertise of fellow US CRO Symbios Clinical.

No financial terms were disclosed for the deal, which will integrate Medpace’s therapeutic resources and global reach with Symbios’ portfolio of services covering the full spectrum of medical device trials, from pre-market to post-approval and post-market/outcomes studies.

Symbios Clinical was founded in 2006 by its chief executive officer, Ryan Wilson, and managing partner, Ethan Rooney. Wilson and the current management team will continue to lead Symbios as part of the Medpace group of companies, as well as retaining their existing base in the Minneapolis, Minnesota area.

The Symbios offering includes trial design, site management, project management, monitoring and data management for device trials in both the US and Europe, with experience in multiple therapy areas including cardiovascular and metabolic diseases.

In January, Medpace raised its European profile by acquiring Medical Consulting Dr Schlichtiger GmbH, a CRO based in Germany with particular expertise in regulatory and drug safety.